Literature DB >> 19957113

Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma.

Giuseppe Procopio1, Elena Verzoni, Emilio Bajetta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19957113     DOI： 10.1007/s12032-009-9371-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  4 in total

1.  Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

Authors:  Ila Tamaskar; Jorge A Garcia; Paul Elson; Laura Wood; Tarek Mekhail; Robert Dreicer; Brian I Rini; Ronald M Bukowski
Journal:  J Urol       Date:  2007-11-12       Impact factor: 7.450

2.  Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.

Authors:  Arkadiusz Z Dudek; Jakub Zolnierek; Anu Dham; Bruce R Lindgren; Cezary Szczylik
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

3.  Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

Authors:  Holger Gerullis; Lothar Bergmann; Luise Maute; Thorsten Holger Ecke; Christoph Eimer; Jens Willem Bagner; Thomas Otto
Journal:  Med Oncol       Date:  2009-04-28       Impact factor: 3.064

4.  Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.

Authors:  Kaja Zimmermann; Alexander Schmittel; Ursula Steiner; Anne Marie Asemissen; Maren Knoedler; Eckhard Thiel; Kurt Miller; Ulrich Keilholz
Journal:  Oncology       Date:  2009-03-24       Impact factor: 2.935
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.